Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Amarin Stock Surged Today

By Cory Renauer - Updated Apr 16, 2019 at 2:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors looking forward to soaring Vascepa sales pushed the shares higher.

What happened

Shares of Amarin (AMRN -3.36%), a company marketing a purified fish-oil pill, popped after the company's J.P. Morgan Healthcare conference presentation. The stock rose 13.6% in midday trading, and was up 9.3% as of 3:53 p.m. EST on Thursday.

Check out the latest Amarin earnings call transcript.

So what

Amarin has been one of 2018's best-performing stocks because its lead drug, Vascepa, produced stunning cardiovascular-event outcome data last September. During the Reduce-It study, patients who added Vascepa to their regular statin therapy were 25% less likely to suffer a heart attack or other major cardiovascular events.

Businessman drawing an upward-sloping chart with his finger

Image source: Getty Images.

The stock gave up some gains in late 2018, due to concerns that the mineral-oil capsules investigators used as a placebo may have elevated cholesterol levels in the control group. During today's investor presentation, Amarin soothed concerns.

Now what

As the only fish-oil capsule of its kind, Amarin can make it rain for investors if the Food and Drug Administration expands its label to include patients who can't control their cholesterol on statin therapy alone. Vascepa is currently approved to treat around 3.8 million Americans with high triglycerides, as an adjunct to diet.

In the first quarter, the company will submit an application that could expand Vascepa's sales many times over, by including cardiac-event reductions for the enormous population of patients on statin therapy with high triglyceride levels.

Fourth-quarter revenue rose to between $72 million and $76 million, which at the low end is a 31% increase compared to the third quarter. In 2019, Amarin expects total revenue to rise more than 50% to around $350 million.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.44 (-3.36%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.